An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

D NA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire board of directors resigned over disagreements with the C ...

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

The news comes as Pfizer is trying to catch up with U.K.-based GlaxoSmithKline (GSK). Its RSV vaccine for adults was approved by the FDA in May. The company is already undergoing priority review with ...

EU regulators are considering withdrawing market authorizations for two hair loss and enlarged prostate treatments over ...

The once-hot Silicon Valley startup has seen its stock’s value decline 99% and is struggling to survive. That has put the ...